Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

Affiliations

Yangling Li: Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China
Dongmei Zhou: Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China
Shuang Xu: Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China
Mingjun Rao: Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China
Zuoyan Zhang: School of Medicine, Zhejiang University City College, Hangzhou 310015, China
Linwen Wu: School of Medicine, Zhejiang University City College, Hangzhou 310015, China
Chong Zhang: School of Medicine, Zhejiang University City College, Hangzhou 310015, China
Nengming Lin: Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China

Abstract

No abstracts available.

ISSN: 2095-3941 (Print)
Publisher: China Anti-Cancer Association
Country of publisher: China
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.cancerbiomed.org/